Drug intelligence / Profile preview

ganitumab + panitumumab

Development stage: Unknown
Lead developer: Amgen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

A combination therapy consisting of ganitumab, a fully human monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R), and panitumumab, a fully human monoclonal antibody targeting epidermal growth factor receptor (EGFR). This combination targets multiple growth factor pathways simultaneously, potentially providing enhanced anti-tumor activity in certain cancer types.

Brand names: Vectibix (panitumumab)

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on ganitumab + panitumumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ganitumab + panitumumab.

Explore the full profile